What's Happening?
Scribe Therapeutics has been awarded over $25 million by the California Institute for Regenerative Medicine (CIRM) to advance its CRISPR-based gene editing therapies targeting cardiometabolic diseases. The funding will support two preclinical programs,
STX-1200 and STX-1400, which aim to lower lipoprotein(a) and triglycerides, respectively. These therapies are designed to provide single-dose, durable treatments for conditions such as atherosclerotic cardiovascular disease and severe hypertriglyceridemia. Scribe's X-Editor (XE) technology, which enhances gene editing precision and specificity, underpins these programs. The funding is part of CIRM's initiative to accelerate promising gene therapy and stem cell research in California.
Why It's Important?
This significant funding from CIRM underscores the potential of CRISPR-based therapies to address unmet medical needs in cardiometabolic diseases, which are leading causes of mortality worldwide. By targeting genetic factors that contribute to cardiovascular disease, Scribe's therapies could offer more effective and long-lasting treatment options compared to current standards. The support from CIRM not only validates Scribe's innovative approach but also highlights the growing investment in genetic medicine as a transformative healthcare solution. Successful development of these therapies could lead to significant advancements in the treatment of cardiovascular diseases, benefiting millions of patients globally.
What's Next?
Scribe will use the CIRM funding to advance its STX-1200 and STX-1400 programs through preclinical development, with the goal of moving these therapies into clinical trials. The company will continue to leverage its CRISPR by Design approach to expand its pipeline of genetic medicines. As these programs progress, Scribe may seek additional partnerships and collaborations to enhance its research and development efforts. The outcomes of these initiatives could have a profound impact on the future of genetic medicine and the treatment of cardiometabolic diseases.
